Related Experiment Video

Updated: Aug 14, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas

S H Lim1, R E Marcus

  • 1Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.

Blood Reviews
|September 1, 1992
PubMed

Insights

Monoclonal antibody (MoAb) therapy offers a new cancer treatment. This review covers MoAb strategies, clinical trial challenges, and their use in non-Hodgkin

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Monoclonal antibody (MoAb) technology has advanced significantly, offering new cancer treatment options.
  • MoAbs are increasingly utilized in targeted cancer therapies.

Purpose of the Study:

  • To review current monoclonal antibody (MoAb) therapy strategies for cancer treatment.
  • To address challenges encountered in early clinical trials of MoAb therapy.
  • To summarize clinical studies of MoAbs in non-Hodgkin's lymphomas.

Main Methods:

  • Literature review of monoclonal antibody (MoAb) therapy strategies.
  • Analysis of challenges and solutions in MoAb clinical trials.
  • Review of clinical studies involving MoAbs for non-Hodgkin's lymphomas.

Main Results:

  • Various MoAb therapy strategies are available for cancer treatment.
  • Early clinical trials of MoAbs have presented specific challenges.
  • MoAbs show promise in treating non-Hodgkin's lymphomas.

Conclusions:

  • Monoclonal antibody (MoAb) therapy is a developing area in cancer treatment.
  • Addressing clinical trial challenges is crucial for MoAb efficacy.
  • Further research into MoAbs for non-Hodgkin's lymphomas is warranted.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.